The best treatment for a genetically driven form of lung cancer continues to show lasting benefits, a new clinical trial update shows. Tagrisso (osimertinib) nearly doubles disease-free survival in earlier-stage patients whose lung cancer is driven by a mutation in their EGFR (epidermal growth factor receptor) gene, researchers report. After four years of follow-up, disease-free… read on > read on >



















